Guzip Biomarkers Corporation is a 2018 spin-out company from Taipei Medical University. Our company has put great effort into developing a diagnostic tool for endometrial cancer.
We are a research-driven company looking forward to providing novel DNA methylation epigenetic biomarkers for applications in the clinic. With a view to providing health management units as the basis for personalized medicine and contributing to improving women’s health, our first project’s goal is to develop an innovative molecular diagnostic test that can be used for endometrial cancer. Our product will be called MPap® DNA Methylation Detection Kit.
Our vision is to be a leading provider dedicated to the women’s healthcare arena, providing accurate, affordable, and safe medical solutions to women. Furthermore, our mission is to pursue the quality of our product, and to constantly innovate.